Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ertapenem sodium, quantity: 1.046 g - injection, powder for - excipient ingredients: sodium bicarbonate; sodium hydroxide - ertapenem is indicated for the treatment of patients, aged 3 months or more, with moderate to severe infections (except meningitis, see precautions) caused by susceptible strains of microorganisms which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics.,ertapenem is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections.,ertapenem is also indicated for the treatment of diabetic foot infections, which require parenteral antibiotic therapy and are caused by susceptible bacterial pathogens which are suspected or proven to be resistant to all other registered antibiotics, or for patients unable to tolerate other antibiotics.,appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. therapy with ertapenem may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy should be adjusted accordingly.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ertapenem sodium, quantity: 1.046 g (equivalent: ertapenem, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate; sodium hydroxide; nitrogen - treatment,ertapenem juno is indicated for the treatment of patients, aged 3 months or more, with moderate to severe infections (except meningitis, see precautions) caused by susceptible strains of microorganisms which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics.,ertapenem juno is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections.,ertapenem juno is also indicated for the treatment of diabetic foot infections, which require parenteral antibiotic therapy and are caused by susceptible bacterial pathogens which are suspected or proven to be resistant to all other registered antibiotics, or for patients unable to tolerate other antibiotics. ,appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. therapy with ertapenem juno may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy,should be adjusted accordingly.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: water for injections - sodium valproate juno is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: hyprolose; calcium silicate; amaranth aluminium lake; titanium dioxide; polyvinyl acetate phthalate; diethyl phthalate; stearic acid; purified talc; povidone; hypromellose; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; citric acid monohydrate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; polyvinyl acetate phthalate; indigo carmine aluminium lake; hyprolose; magnesium stearate; povidone; stearic acid; amaranth aluminium lake; diethyl phthalate; purified talc; macrogol 6000; calcium silicate; hypromellose; titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ertapenem as sodium - powder for solution for inj/inf - ertapenem as sodium 1 g/vial - ertapenem - ertapenem s.k. is indicated for the treatment of adult patients and pediatric patients ( 3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms. - complicated intra-abdominal infections. - complicated skin and skin structure infections including diabetic foot infections without osteomyelitis. - community acquired pneumonia. - complicated urinary tract infections including pyelonephritis. acute pelvic infections including postpartum endomyometritis septic abortion and post surgical gynecologic infections

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem sodium - bacterial infections - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4.4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ertapenem, quantity: 1 g (equivalent: ertapenem sodium, qty 1.046 g) - injection, powder for - excipient ingredients: sodium hydroxide; sodium bicarbonate - invanz is indicated for the treatment of adult patients with moderate to severe infections caused by susceptible strains of microorganisms, which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics. invanz is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections. appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. therapy with invanz may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy should be adjusted accordingly.,invanz is indicated for the treatment of patients, aged 3 months or more, with moderate to severe infections (except meningitis, see precautions) caused by susceptible strains of micro-organisms which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics. invanz is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections. invanz is also indicated for treatment of diabetic foot infections, which require parenteral antibiotic therapy and are caused by susceptible bacterial pathogens which are suspected or proven to be resistant to all other registered antibiotics, or for patients unable to tolerate other antibiotics. appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. therapy with invanz may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy should be adjusted accordingly.